| dc.identifier.citation | Adriani, W., Fauzi, Z. A., & Rahayu, W. (2015). Gambaran Nilai SGOT Dan SGPT Pasien Tuberkulosis Paru Yang Dirawat Inap Di Rsud Arifin Achmad Provinsi Riau Tahun 2013. Jom Fk, 2(3), 1576–1580. Alqarni, F., Alsubaie, M. F., Mahmoud, M., Wajid, S., Alzaharni, S., Almajid, M., Elkarouri, M., Haddad, Q., Alghamdi, A., & Alqahatani, A. (2022). Baseline Hypoalbuminemia as a Risk Factor for Antituberculosis Drug-Induced Hepatotoxicity. Latin American Journal of Pharmacy, 41(9), 1779–1785. Ananda Sulistya, D., Aryani Perwitasari, D., & Dahlan, A. (2022). Monitoring Efek Samping Hepatotoksisitas Obat Antituberkulosis Di Rs X Yogyakarta Monitoring Side Effects of Hepatotoxicity of Antituberkulosis Drug At Hospital X Yogyakarta. Agustus, IX(2), 1–8. http://dx.doi.org/10.47653/farm.v9i2.601 Aruningtyas, D. (2009). Pengaruh Faktor-Faktor Risiko Terhadap Ketaatan Pengobatan Pada Pasien Tuberkulosis Rawat Jalan Di Balai Pengobatan Penyakit Paru-Paru Kebumen Periode Oktober 2008-Maret 2009. Azizi, F. H., Husin, U. A., & Rusmartini, T. (2015). Gambaran karakteristik tuberkulosis paru dan ekstra paru di BBKPM Bandung tahun 2014. Posiding Penelitian Sivitas Akademika Unsiba, 860–866. Azzahro, D. (2015). Gambaran Penderita Tuberculosis Multi Drug Resisten ( TB MDR ) Di RSUD Dr . H . Abdul Moeloek Provinsi Lampung Januari-Desember 2015 Description Of Tuberculosis Multi Drug Resisten ( MDR TB ) Patients In RSUD Dr . H . Abdul Moeloek Province Lampung. Ejurnal.Poltekkes-Tjk.Ac.Id, 6(1), 640–648. http://ejurnal.poltekkes-tjk.ac.id/index.php/JANALISKES/article/view/790 Bangwal, R., Hussain, M. M. E., Saklani, S., Mathur, P., & Joshi, Y. (2020). Hepatotoxicity Induced by Anti-Tubercular Drugs Therapy: A Case Report. Journal of Drug Delivery and Therapeutics, 10(5-s), 195–198. https://doi.org/10.22270/jddt.v10i5-s.4463 Clarasanti, I., Wongkar, M. C. P., & Waleleng, B. J. (2016). Gambaran enzim transaminase pada pasien tuberkulosis paru yang diterapi dengan obat-obat anti tuberkulosis di RSUP Prof. Dr. R. D. Kandou Manado. E-CliniC, 4(1), 1–6. https://doi.org/10.35790/ecl.4.1.2016.12102 Darliana, D. (2011). Manajemen Pasien Tuberculosis Paru - Management of Lung TB for Patient. PSIK-FK Unsyiah, 11(1), 27–31. Devarbhavi H, Singh R, Patil M, Sheth K, A. C., & G, B. (2013). Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis druginduced liver injury. J Gastroenterol Hepatol., 28((1)), 161. Djauhari, T. (2019). Pre Eliminary Study : Pengaruh Pemberian First Line Drug Antituberculosis Terhadap Jumlah Hydropic Swelling Pada Sel Hepar Tikus Putih Jantan (Rattus Novergicus Strain Wistar) Yang Diinduksi Selama dua Minggu”. Saintika Medika, 15(1), 60. https://doi.org/10.22219/sm.vol15.smumm1.8484 Firdayanti, F. (2019). Gambaran Kadar Bilirubin Total pada Penderita Tuberkulosis Paru dengan Terapi Obat Anti Tuberkulosis (Oat) di Puskesmas Poasia Kota Kendari. Jurnal Kesehatan Vokasional, 4(3), 118. https://doi.org/10.22146/jkesvo.44487 Hoofnagle, J. H. (n.d.). Severity Grading In Drug Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/ Kemenkes RI. (2020a). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Nomor HK.01.07/MENKES/755/2019 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis (Vol. 59). Kemenkes RI. (2020b). Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020-2024. Pertemuan Konsolidasi Nasional Penyusunan STRANAS TB, 135. Kirana, P. N. (2018). Gambaran Kadar Serum Glutamic PiruvicTransaminase (SGPT) Pada Juru Parkir Di Jl. Ahmad Yani Kabupaten Jombang. Kristini, T., & Hamidah, R. (2020). Potensi Penularan Tuberculosis Paru pada Anggota Keluarga Penderita. Jurnal Kesehatan Masyarakat Indonesia, 15(1), 24. https://doi.org/10.26714/jkmi.15.1.2020.24-28 Liu, L., Li, X., Huang, C., Bian, Y., Liu, X., Cao, J., Qu, W., & Miao, L. (2020). Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs. Expert Opinion on Drug Metabolism and Toxicology, 16(6), 527–537. https://doi.org/10.1080/17425255.2020.1758060 Luthariana, L., Karjadi, T. H., Hasan, I., & Rumende, C. M. (2017). Faktor Risiko Terjadinya Hepatotoksisitas Imbas Obat Antituberkulosis pada Pasien HIV/AIDS. Jurnal Penyakit Dalam Indonesia, 4(1), 23. https://doi.org/10.7454/jpdi.v4i1.109 Mar’iyah, K., & Zulkarnain. (2021). Patofisiologi penyakit infeksi tuberkulosis. Prosiding Seminar Nasional Biologi, 7(November), 88–92. Mustikawati, D. E. A. S. (2011). Strategi Nasional Pengendalian TB. Kementrian Kesehatan Indonesia Direktorat Jenderal Pengendalian Penyakit Dan Penyehatan Lingkungan 2011. Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O’Brien, R., … Vernon, A. (2016). Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. In Clinical Infectious Diseases (Vol. 63, Issue 7). https://doi.org/10.1093/cid/ciw376 Pontoh, L. G., Polii, E. B. ., & Gosal, F. (2016). Gambaran kadar bilirubin pasien tuberkulosis paru selama pengobatan di RSUP Prof. ECl, 4(1), 63–70. Rahayu, E. S., Sukeksi, A., & Nuroini, F. (2017). Hubungan Kadar SGOT-SGPT Pada Pasien TB Pengobatan Fase Awal Di Puskesmas Pati. Repository Unimus, 1–6. Riskesdas. (2018). Laporan Riskesdas 2018 Kementrian Kesehatan Republik Indonesia. In Laporan Nasional Riskesdas 2018 (Vol. 53, Issue 9, pp. 154–165). http://www.yankes.kemkes.go.id/assets/downloads/PMK No. 57 Tahun 2013 tentang PTRM.pdf Robiyanto, R., Liana, J., & Purwanti, N. U. (2019). Kejadian Obat-Obatan Penginduksi Kerusakan Liver pada Pasien Sirosis Rawat Inap di RSUD Dokter Soedarso Kalimantan Barat. Jurnal Sains Farmasi & Klinis, 6(3), 274. https://doi.org/10.25077/jsfk.6.3.274-285.2019 Rosida, A. (2016). Pemeriksaan Laboratorium Penyakit Hati. Berkala Kedokteran, 12(1), 123. https://doi.org/10.20527/jbk.v12i1.364 Veryanti, P. R., Dewi, N. P. K., & Pertiwi, D. (2019). Potensi Interaksi Obat Anti Tuberkulosis di Instalasi Rawat Inap RSUD X Jakarta Periode 2016. Saintech Farma: Jurnal Ilmu Kefarmasian, 12(1), 23–31. Wahyudi, A. D., & Soedarsono, S. (2019). Farmakogenomik Hepatotoksisitas Obat Anti Tuberkulosis. Jurnal Respirasi, 1(3), 103. https://doi.org/10.20473/jr.v1-i.3.2015.103-108 Wesnawa, M. A. D. P., & Kusmiati, T. (2020). Drug Induced Hepatitis pada Tuberkulosis Paru dengan Multisite Tuberkulosis Ekstraparu. Jurnal Respirasi, 5(2), 34. https://doi.org/10.20473/jr.v5-i.2.2019.34-40 Widodo, & Chairini, S. (2020). Gambaran Pemeriksaan Kadar SGOTdan SGPT pada Penderita Tuberkulosis Paru. Jaringan Laboratorium Medis, 02(01), 34–37. World Health Organization. (2021). Global Tuberculosis Report. Younossian, A. B., Rochat, T., Ketterer, J. P., Wacker, J., & Janssens, J. P. (2005). High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tubercolosis. European Respiratory Journal, 26(3), 462–464. https://doi.org/10.1183/09031936.05.00006205 | id_ID |
